Takeda receives FDA approval for rusfertide as treatment for polycythemia vera
The U.S. Food and Drug Administration (FDA) has approved Takeda Pharmaceutical's Mimrylo (rusfertide), a first-in-class therapy for the rare blood disorder polycythemia vera. Mimrylo functions by mimicking hepcidin, a hormone responsible for regulating iron levels in the body. By limiting excess iron used to produce new red blood cells, the drug aims to manage symptoms of this chronic condition more effectively than existing treatments. This approval marks an important milestone for Takeda and offers patients with polycythemia vera a novel therapeutic option.
Tickers: $TAK